Breaking News Instant updates and real-time market news.

QCOM

Qualcomm

$75.66

0.23 (0.30%)

, ABT

Abbott

$83.11

-0.69 (-0.82%)

09:09
07/17/19
07/17
09:09
07/17/19
09:09

Fly Intel: Pre-market Movers

HIGHER: Qualcomm (QCOM), up 4% after the U.S. Justice Department asked a federal appeals court to halt the enforcement of a broad antitrust ruling against the company... Orion Group (ORN), up 8% after announcing contract awards totaling approximately $52M. UP AFTER EARNINGS: Abbott (ABT), up 2%... ASML (ASML), up 6%... Seattle Genetics (SGEN), up 9%. DOWN AFTER EARNINGS: Textron (TXT), down 3%... Comerica (CMA), down 3%... Nu Skin (NUS), down 23%... CSX (CSX), down 7%. LOWER: Immuron (IMRN), down 15% after its 339K share spot secondary priced at $4.00 per share.

QCOM

Qualcomm

$75.66

0.23 (0.30%)

ABT

Abbott

$83.11

-0.69 (-0.82%)

ASML

ASML

$205.06

-1.57 (-0.76%)

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

TXT

Textron

$54.02

0.59 (1.10%)

CMA

Comerica

$71.75

0.39 (0.55%)

NUS

Nu Skin

$45.50

1.44 (3.27%)

CSX

CSX

$79.57

1.05 (1.34%)

IMRN

Immuron

$4.27

1.43 (50.35%)

ORN

Orion Group

$3.76

0.02 (0.53%)

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 31

    Jul

  • 06

    Aug

  • 06

    Aug

  • 26

    Aug

  • 26

    Aug

  • 09

    Sep

  • 13

    Nov

  • 17

    Jul

QCOM Qualcomm
$75.66

0.23 (0.30%)

06/18/19
MSCO
06/18/19
NO CHANGE
Target $95
MSCO
Overweight
Qualcomm share ownership 'still worth the noise,' says Morgan Stanley
Morgan Stanley analyst James Faucette said being a Qualcomm (QCOM) shareholder has "always required a bit more mettle" given its history of political and legal risks, but he thinks that at current levels the stock is "still worth the noise." Faucette reduced his FY19 and FY20 estimates slightly because he no longer assumes Apple (AAPL) will refresh its portfolio to include more Qualcomm-based legacy models in late 2019 and most of FY20 and also to be more conservative in his assumption of Huawei's contribution. However, he is now modeling more impact from an uplift in 5G average selling prices and thinks if Huawei handsets are absorbed by other OEMs that Qualcomm could see a positive impact, Faucette noted. The analyst, who projects Qualcomm's FY21 earnings at about $6.80 per share, keeps an Overweight rating and $95 price target on the stock.
07/12/19
MZHO
07/12/19
NO CHANGE
Target $68
MZHO
Neutral
Qualcomm price target raised to $68 from $65 at Mizuho
Mizuho analyst Vijay Rakesh raised his price target for Qualcomm to $68 from $65 citing improved multiples in the semiconductor space. The analyst, however, reiterates a Neutral rating on the shares. The company's near-term outlook "could be soft" given weak handsets trends and potentially lower 5G royalty rates in the second half of 2019, Rakesh tells investors in a research note.
07/17/19
MSCO
07/17/19
NO CHANGE
Target $95
MSCO
Overweight
Court stay fastest route to rebuilding case for Qualcomm, says Morgan Stanley
Following media reports that the Department of Justice, Department of Defense and Department of Energy all asked the 9th Circuit Court to stay the antitrust ruling against Qualcomm, Morgan Stanley analyst James Faucette said he believes that a court-ordered stay, or even getting the ruling overturned, would be the fastest way to rebuild the investment case for the stock. While he has expressed the opinion that the actual impact of the ruling would ultimately be negligible, a speedy stay that leads to an overturning, or at least penalties, will have a "much bigger impact on long-term investor sentiment than a slow-drip process," Faucette contends. He keeps an Overweight rating and $95 price target on Qualcomm shares.
06/11/19
RAJA
06/11/19
NO CHANGE
RAJA
Broadcom, Apple deal closes door on Qualcomm/Qorvo, says Raymond James
Raymond James analyst Chris Caso notes that Broadcom (AVGO) disclosed that it had signed a 2-year contract with Apple (AAPL) for the sale of RF components, similar to a 3-year contract between Broadcom and Apple signed in 2016 but now with the latter sourcing "all of its requirements for such RF front end components and modules" from Broadcom. The analyst believes this closes the door on Qualcomm (QCOM) getting RF content in the 2020 iPhone, while maintaining the status quo for Skyworks (SWKS), which supplied the low band PAD and diversity receive through the term of the last Broadcom/Apple contract. Additionally, Caso thinks the Broadcom agreement also closes the door on the mid/high band opportunity at Apple for Qorvo (QRVO) through 2020.
ABT Abbott
$83.11

-0.69 (-0.82%)

04/29/19
PIPR
04/29/19
NO CHANGE
Target $165
PIPR
Overweight
Piper reiterates Overweight on DexCom after 'robust' teen survey results
There were 8,042 responses to Piper Jaffray's teen survey in February and March, of which 1,707 have diabetes or a member of their household does, analyst JP McKim tells investors in a research note. The survey implies underlying continuous glucose monitoring market growth of close to 58%, says the analyst. Abbott (ABT) reported 70% Libre growth in Q1 and DexCom (DXCM) reports May 1, McKim points out. He expects "continued strong growth" from DexCom following the "robust" survey results and reiterates an Overweight rating on the shares with a $165 price target.
04/15/19
RBCM
04/15/19
NO CHANGE
Target $82
RBCM
Sector Perform
Abbott price target raised to $82 from $77 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Abbott to $82 ahead of its Q1 results, saying the "pattern of revenue growth" seen last year should continue this quarter as Core Laboratory, Electrophysiology, Structural Heart, and Diabetes Care product categories "lead the way." The analyst also expects Abbott's organic revenue growth in the Medical Devices segment to come at the high end of guidance, adding that while his new price target implies a multiple of 22.5-times vs. peer group's 21-times, he believes that the company's growth profile justifies the valuation premium. Henry recommends that investors buy the stock on "any weakness".
04/18/19
LSCM
04/18/19
NO CHANGE
Target $100
LSCM
Buy
Investors should buy into Tandem Diabetes 'fire sale,' says Lake Street
Lake Street analyst Brooks O'Neil attributes the recent selloff in shares of Tandem Diabetes (TNDM) to investor fears related to the potential implications of "Medicare For All." Yesterday, the decline also appeared to "draw fuel from the strong growth" Abbott (ABT) reported for its Libre glucose monitor for diabetics, O'Neil tells investors in a research note titled "Fire Sale. Should You Buy? Yes. There Is No Fire. Affirm BUY, $100 PT." The analyst doubts the healthcare system will be changed significantly and on Libre, he says, "We're sorry, but we believe investors are either badly confused or just plain wrong." Abbott offers a low-cost version of the monitoring system but does not compete in any way with Tandem in its pump market, says the analyst. Rather, O'Neil thinks there are "potentially significant positives" for Tandem Diabetes related to the "enormous success" of Abbott's Libre franchise. The analyst sees an "extraordinarily positive" outlook for Tandem Diabetes and recommends buying the shares on the recent pullback. He affirms a Buy rating on the shares with a $100 price target.
04/03/19
JPMS
04/03/19
NO CHANGE
Target $175
JPMS
Overweight
JPMorgan remains 'very bullish' on DexCom despite Libre 2.0 uncertainty
The latest DexCom (DXCM) controversy is "whirling speculation" around Abbott's (ABT) Libre 2.0 launch, JPMorgan analyst Robbie Marcus tells investors in a research note. The analyst keeps an Overweight rating on DexCom shares with a $175 price target but expects uncertainty over Libre 2.0 to remain an overhang until it receives U.S. approval. However, he remains "very bullish" on the shares and sees "significant upside" to 2019 estimates. DexComis the best positioned in diabetes longer-term, Marcus contends.
ASML ASML
$205.06

-1.57 (-0.76%)

06/19/19
WELS
06/19/19
INITIATION
WELS
Outperform
ASML initiated with an Outperform at Wells Fargo
Wells Fargo analyst Joe Quatrochi initiated ASML with an Outperform rating and a $230 price target. Quatrochi cited ASML's position as sole provider of extreme ultravioet, or EUV, lithography technology, potential gross margin upside drivers looking to next year as EUV adoption and related services increase ramp ups, and the company's installed base management business, which the analyst believes could be underappreciated.
06/19/19
WELS
06/19/19
INITIATION
WELS
Outperform
ASML initiated with an Outperform at Wells Fargo
07/08/19
SOCG
07/08/19
INITIATION
SOCG
Buy
ASML initiated with a Buy at Societe Generale
Societe Generale started ASML with a Buy rating and 220 euro price target. The firm calls the company the "king" of the extreme ultraviolet lithography era.
07/15/19
SANT
07/15/19
DOWNGRADE
SANT
Hold
ASML downgraded to Hold from Buy at Santander
SGEN Seattle Genetics
$63.12

-0.87 (-1.36%)

07/17/19
PIPR
07/17/19
UPGRADE
Target $75
PIPR
Overweight
Seattle Genetics upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro upgraded Seattle Genetics to Overweight from Neutral and raised his price target for the shares to $75 from $64. The company reported Q2 Adcetris revenue of $159M, beating consensus of $149M and reversing the trend of low single-digit quarter-over-quarter growth observed over the last three quarters, Catanzaro tells investors in a research note. Further, the analyst's survey work and conversations with key opinion leaders suggests that enfortumab vedotin is poised to see strong uptake in post-chemo/check-point inhibitors UBC. He believes Seattle Genetics' 2019 guidance of $610M-$640M is "well within reach" while it has the opportunity to report positive data from multiple potential registration trials over the next 12 months.
03/28/19
PIPR
03/28/19
NO CHANGE
PIPR
Neutral
Seattle Genetics' ORR 'impressive' for third-line UBC, says Piper Jaffray
After Seattle Genetics (SGEN) reported topline results from the first cohort of patients in a phase 2 trial evaluating enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received two prior lines of treatment, Piper Jaffray analyst Joseph Catanzaro said the 44% objective response rate, or ORR, was "impressive" in this population of patients. While he thinks there may be room for upward revisions to his assumptions, he prefers to wait for the full data set before making any changes. Catanzaro keeps a Neutral rating on Seattle Genetics, citing his concerns about the growth of Adcetris.
04/10/19
STFL
04/10/19
INITIATION
Target $70
STFL
Hold
Seattle Genetics initiated with a Hold at Stifel
Stifel analyst Stephen Willey initiated Seattle Genetics with a Hold rating and a price target of $70, saying that while the company "commands a leadership position in the development of antibody-drug conjugate technology", the current ADCETRIS estimates as "much-too-optimistic" in suggesting trajectory to sales of over $1B. The analyst adds that although the "recently-announced phase data for enfortumab vedotin will initiate Seattle Genetics' transition to a multi-product commercial company", he sees the "presumption of clinical/commercial success to be appropriately risk-adjusted in the stock at these levels."
04/25/19
PIPR
04/25/19
NO CHANGE
Target $64
PIPR
Neutral
Seattle Genetics Q1 marks third quarter of 'sluggish growth', says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro is keeping his Neutral rating and $64 price target on Seattle Genetics after its Q1 results that saw Adcetris sales of $135M missing consensus of $141M. The analyst notes that this marks the 3rd consecutive quarter of "sluggish growth", also lowering his FY19 EPS outlook to ($1.05) from (94c) and FY20 outlook to (14c) from 12c. Catanzaro lowers his FY19 Adcetris sales forecast to $611M from $633M, adding that the company's Adcentris revenue outlook of $610M-$640M for this year may "prove difficult."
TXT Textron
$54.02

0.59 (1.10%)

01/08/19
JEFF
01/08/19
NO CHANGE
Target $59
JEFF
Buy
Textron removed from Franchise Pick list at Jefferies
Jefferies analyst Sheila Kahyaoglu removed Textron from her firm's Franchise Pick list and lowered her price target for the shares to $59 from $68. The analyst continues to like Textron's potential to capture market share, but she believes consensus forecasts are likely too high for 2019. Kahyaoglu keeps a Buy rating on Textron.
01/10/19
SUSQ
01/10/19
INITIATION
Target $52
SUSQ
Neutral
Textron initiated with a Neutral at Susquehanna
Susquehanna analyst Charles Minervino initiated Textron with a Neutral rating as its largest business, Textron Aviation, is in the midst of what will likely be a multi-year upcycle in business jet orders. Coupled with new product launches, the cycle should be an attractive tailwind for orders revenue growth and margin expansion. However, he believes the potential large-scale orders in Aviation and Bell are at least partially factored in already and notes that his 2019-2020 EPS estimates are slightly below consensus. Minervino has a $52 price target on Textron shares.
04/01/19
FBCO
04/01/19
INITIATION
FBCO
Neutral
Textron initiated with a Neutral at Credit Suisse
04/01/19
04/01/19
INITIATION
Target $50

Neutral
Textron started with Neutral at Credit Suisse on strong positions, mixed markets
As previously reported, Credit Suisse analyst Robert Spingarn initiated coverage of Textron with a Neutral rating and a $50 price target. The analyst notes that Textron is a market leader in many of its markets, including executive aviation, commercial rotorcraft, and specialized vehicles. However, many of these markets have low visibility and/or soft growth, which often require competitive pricing as well as continual product investment, he contended.
CMA Comerica
$71.75

0.39 (0.55%)

07/12/19
SBSH
07/12/19
DOWNGRADE
SBSH
Sell
Comerica downgraded to Sell from Neutral at Citi
Citi analyst Keith Horowitz downgraded Comerica to Sell from Neutral.
07/12/19
SBSH
07/12/19
NO CHANGE
SBSH
Morgan Stanley upgrade, Wells downgrade among Citi's bank changes
Citi analyst Keith Horowitz made seven rating changes in the U.S. Banks space after updating his estimates and target prices for a new base case rate forecast that more closely reflects the forward curve. This includes two interest rate cuts in 2019 and 2020. The analyst's terminal yield curve assumptions to Fed Funds is 1.75%. The lower rate assumptions led him to lower his normal return on tangible equity estimates ~100 basis points on average. Following these changes, Horowitz upgraded Morgan Stanley (MS) to Buy from Neutral), downgraded Comerica (CMA), Northern Trust (NTRS), and M&T Bank (MTB) to Sell from Neutral, and downgraded Wells Fargo (WFC), Citizens Financial (CFG), and Fifth Third (FITB) to Neutral from Buy.
07/11/19
BOFA
07/11/19
DOWNGRADE
BOFA
Underperform
BofA double downgrades Comerica to Underperform, cuts Regions to Neutral
BofA Merrill Lynch analyst Erika Najarian downgraded Comerica two notches, to Underperform from Buy, citing the cloudier visibility on forward EPS given the more challenging backdrop. However, she noted that this rating change was not a call on the quarter but more about the environment for banks moving forward. Najarian also downgraded Regions Financial (RF) to Neutral from Buy, citing similar concerns.
07/11/19
BOFA
07/11/19
DOWNGRADE
BOFA
Underperform
Comerica downgraded to Underperform from Buy at BofA/Merrill
NUS Nu Skin
$45.50

1.44 (3.27%)

07/03/19
STFL
07/03/19
NO CHANGE
Target $45
STFL
Sell
Stifel keeps Sell on Nu Skin after Usana cuts outlook on China
Nu Skin Enterprises (NUS) competitor Usana last night announced preliminary Q2 results with sales 17% below consensus and the company also lowered full year sales and earnings guidance 16% and 25%, respectively, at the midpoint, Stifel analyst Mark Astrachan tells investors in a research note. Usana's downside is largely due to softer than expected sales in China, which the company expects will continue throughout 2019, the analyst adds. He points out that increased promotional activity in China did not generate meaningful sales and customer growth. Astrachan says this is consistent with the risks noted in his downgrade of Nu Skin shares to Sell. The analyst is now more cautious on China and keeps a Sell rating on Nu Skin shares with a $45 price target.
07/17/19
DADA
07/17/19
DOWNGRADE
Target $38
DADA
Neutral
Nu Skin downgraded to Neutral from Buy at DA Davidson
DA Davidson analyst Linda Bolton Weiser downgraded Nu Skin to Neutral from Buy and slashed her price target on the shares to $38 from $88 after the company pre-announced a Q2 revenue and earnings miss, noting that media scrutiny has impacted consumer sentiment and that the meeting ban for direct sellers in China was not lifted in the quarter as the company had anticipated. However, Weiser added that she does not believe the company's dividend is in danger of being reduced or cut unless the meeting ban and revenue declines continue for "many years."
07/17/19
JEFF
07/17/19
DOWNGRADE
Target $40
JEFF
Hold
Jefferies downgrades Nu Skin to Hold, halves price target to $40
Jefferies analyst Stephanie Wissink downgraded Nu Skin Enterprises to Hold from Buy and cut her price target for the shares to $40 from $80. Citing China, Nu Skin issued a ~6% downward revision to Q2 and 11% to full year sales, Wissink tells investors in a research note. She expects the shares to correct at least 17%, which is the drop in earnings guidance, as "legitimate questions around inherent risks have resurfaced." The value of Nu Skin's business will be discounted until the China overhang clears, Wissink contends.
07/17/19
JEFF
07/17/19
DOWNGRADE
Target $40
JEFF
Hold
Nu Skin downgraded to Hold from Buy at Jefferies
Jefferies analyst Stephanie Wissink downgraded Nu Skin Enterprises to Hold from Buy and cut her price target for the shares to $40 from $80.
CSX CSX
$79.57

1.05 (1.34%)

07/17/19
FBCO
07/17/19
NO CHANGE
Target $86
FBCO
Outperform
CSX price target lowered to $86 from $92 at Credit Suisse
Credit Suisse analyst Allison Landry lowered her price target for CSX to $86 from $92 as the company lowered its 2019 revenue guide. The analyst reiterates an Outperform rating on the shares.
07/17/19
SPHN
07/17/19
DOWNGRADE
Target $79
SPHN
Equal Weight
CSX downgraded to Equal Weight on revenue headwinds at Stephens
As previously reported, Stephens analyst Justin Long downgraded CSX to Equal Weight from Overweight after the company reported Q2 results that missed consensus, reduced its revenue guidance and provided more muted commentary on demand. Given headwinds from a softer economy, loose truckload capacity, weaker coal fundamentals, the loss of a crude-by-rail customer that represented 1% of volumes and tougher comps, Long said he thinks revenue trends could remain under meaningful pressure for six to twelve months. He cut his price target on CSX shares to $79 from $86.
07/17/19
SPHN
07/17/19
DOWNGRADE
SPHN
Equal Weight
CSX downgraded to Equal Weight from Overweight at Stephens
07/17/19
RBCM
07/17/19
NO CHANGE
Target $75
RBCM
Sector Perform
CSX price target lowered to $75 from $78 at RBC Capital
RBC Capital analyst Walter Spracklin lowered his price target on CSX to $75 and kept his Sector Perform rating after its weaker than expected Q2 results and a cut in revenue guidance, which he expects to have a "pronounced negative impact" on the stock price and across the rail sector. The analyst cites the commentary from CSX CEO referring to the current economic backdrop as "the most puzzling I have experienced in my career" in evidence of the prevailing macro risk for the company going forward. Spracklin adds that the muted earnings growth potential, along with the negative implied return of his price target, warrants a neutral stance on the stock.
IMRN Immuron
$4.27

1.43 (50.35%)

ORN Orion Group
$3.76

0.02 (0.53%)

07/08/19
RILY
07/08/19
UPGRADE
Target $5
RILY
Buy
B. Riley FBR upgrades Orion Group to Buy, says pullback overdone
B. Riley FBR analyst Alex Rygiel upgraded Orion Group to Buy from Neutral and raised his price target for the shares to $5 from $4. The recent weakness in the shares, partly due to deletion from the Russell 2000 index, was overdone, Rygiel tells investors in a research note. He believes Orion's turnaround is in process, "strong" new awards in Q2 provides the foundation for a financial rebound, and that the shares are attractively valued at current levels.
07/08/19
07/08/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JetBlue (JBLU) upgraded to Neutral from Underperform at Credit Suisse with analyst Jose Caiado citing summer leisure strength and manageable 2020 expectations. 2. Johnson Controls (JCI) upgraded to Neutral from Underweight at JPMorgan with analyst Stephen Tusa saying the stock has "de-rated" and the company's fundamentals look more stable now relative to peers. 3. Orion Group (ORN) upgraded to Buy from Neutral at B. Riley FBR with analyst Alex Rygiel saying the recent weakness in the shares, partly due to deletion from the Russell 2000 index, was overdone. 4. Life Storage (LSI) upgraded to Outperform from Market Perform at Raymond James with analyst Jonathan Hughes saying his upgrade was driven by a more attractive valuation, managements focus on improving portfolio quality, and its relative size versus peers that allows for more impactful external growth. 5. Cabot Oil & Gas (COG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Nitin Kumar saying he believes the company is more immune to oil price volatility and that it has long embraced the strategy of curtailing activity to increase shareholder capital return. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/18
RILY
10/19/18
DOWNGRADE
Target $7
RILY
Neutral
Orion Group downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Alex Rygiel downgraded Orion Group to Neutral and lowered his price target for the shares to $7 from $11 after the company's preliminary Q3 results missed expectations.
07/08/19
RILY
07/08/19
UPGRADE
Target $5
RILY
Buy
Orion Group upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Alex Rygiel upgraded Orion Group to Buy from Neutral and raised his price target for the shares to $5 from $4.

TODAY'S FREE FLY STORIES

HGV

Hilton Grand Vacations

$32.60

-0.08 (-0.24%)

12:06
10/14/19
10/14
12:06
10/14/19
12:06
Hot Stocks
Breaking Hot Stocks news story on Hilton Grand Vacations »

Hilton Grand Vacations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RARE

Ultragenyx

$42.08

-0.69 (-1.61%)

12:05
10/14/19
10/14
12:05
10/14/19
12:05
Conference/Events
Ultragenyx participates in a conference call with JPMorgan »

Large Cap Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

GGAL

Grupo Financiero

$12.99

-0.06 (-0.46%)

12:05
10/14/19
10/14
12:05
10/14/19
12:05
Options
Grupo Financiero call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:55
10/14/19
10/14
11:55
10/14/19
11:55
Conference/Events
JPMorgan telecom/networking equip analyst holds analyst/industry conference call »

Telecom & Networking…

VST

Vistra Energy

$27.00

-0.08 (-0.30%)

11:55
10/14/19
10/14
11:55
10/14/19
11:55
Options
Vistra Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SDC

SmileDirectClub

$10.11

-0.99 (-8.92%)

11:50
10/14/19
10/14
11:50
10/14/19
11:50
On The Fly
SmileDirectClub drops after Dental Board of California sunset bill signed »

Shares of SmileDirectClub…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

RVNC

Revance

$13.01

0.84 (6.90%)

11:47
10/14/19
10/14
11:47
10/14/19
11:47
Recommendations
Revance analyst commentary  »

Stifel surprised by CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

HAL

Halliburton

$18.43

-0.515 (-2.72%)

11:45
10/14/19
10/14
11:45
10/14/19
11:45
Options
Halliburton call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 13

    Nov

NKE

Nike

$94.87

0.97 (1.03%)

, WDC

Western Digital

$59.11

0.75 (1.29%)

11:41
10/14/19
10/14
11:41
10/14/19
11:41
On The Fly
Nike, Western Digital upgrades among today's top analyst calls »

Check out today's top…

NKE

Nike

$94.87

0.97 (1.03%)

WDC

Western Digital

$59.11

0.75 (1.29%)

TPR

Tapestry

$24.94

-1.03 (-3.97%)

HPE

HP Enterprise

$14.77

0.42 (2.93%)

XLNX

Xilinx

$96.33

0.15 (0.16%)

DAL

Delta Air Lines

$52.71

-0.23 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 07

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

SDC

SmileDirectClub

$10.33

-0.77 (-6.94%)

11:32
10/14/19
10/14
11:32
10/14/19
11:32
Recommendations
SmileDirectClub analyst commentary  »

SmileDirectClub may have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

INTC

Intel

$51.65

-0.41 (-0.79%)

11:28
10/14/19
10/14
11:28
10/14/19
11:28
Periodicals
Intel may skip 10nm for desktop CPUs, Wccftech reports »

Intel is planning to skip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 20

    Nov

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

, FB

Facebook

$183.97

-0.23 (-0.12%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Periodicals
Booking Holdings no longer supporting Facebook's Libra cryptocurrency, CNBC says »

CNBC Now tweeted…

BKNG

Booking Holdings

$1,985.99

11.08 (0.56%)

FB

Facebook

$183.97

-0.23 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 30

    Oct

M

Macy's

$15.17

-0.56 (-3.56%)

11:25
10/14/19
10/14
11:25
10/14/19
11:25
Options
Macy's call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

CARA

Cara Therapeutics

$19.13

0.29 (1.54%)

11:22
10/14/19
10/14
11:22
10/14/19
11:22
Recommendations
Cara Therapeutics analyst commentary  »

Stifel still optimistic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZUL

Azul

$37.10

0.25 (0.68%)

, UAL

United Airlines

$86.50

-0.68 (-0.78%)

11:20
10/14/19
10/14
11:20
10/14/19
11:20
Periodicals
Azul in talks to join United, Copa, Avianca partnership, Reuters reports »

Brazilian airline Azul…

AZUL

Azul

$37.10

0.25 (0.68%)

UAL

United Airlines

$86.50

-0.68 (-0.78%)

CPA

Copa Holdings

$98.68

-0.67 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 12

    Nov

  • 14

    Nov

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
10/14/19
10/14
11:17
10/14/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
10/14/19
10/14
11:16
10/14/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$20.96

0.305 (1.48%)

11:15
10/14/19
10/14
11:15
10/14/19
11:15
Options
Kemet put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

I

Intelsat

$24.59

0.26 (1.07%)

11:05
10/14/19
10/14
11:05
10/14/19
11:05
Options
Intelsat call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$169.81

-1.16 (-0.68%)

11:03
10/14/19
10/14
11:03
10/14/19
11:03
Hot Stocks
Deere to acquire Unimil, terms not disclosed »

Deere & Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

SDC

SmileDirectClub

$10.48

-0.62 (-5.59%)

11:01
10/14/19
10/14
11:01
10/14/19
11:01
Hot Stocks
Breaking Hot Stocks news story on SmileDirectClub »

SmileDirectClub says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

SDC

SmileDirectClub

$10.44

-0.66 (-5.95%)

11:00
10/14/19
10/14
11:00
10/14/19
11:00
Hot Stocks
SmileDirectClub says CA assembly bill 1519 creates 'unnecessary hurdles' »

SmileDirectClub issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

TPR

Tapestry

$24.69

-1.28 (-4.93%)

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Options
Tapestry put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

10:55
10/14/19
10/14
10:55
10/14/19
10:55
Conference/Events
Evercore REITs analyst to hold a luncheon »

REITs Analyst Sakwa holds…

PUBGY

Publicis

$0.00

(0.00%)

, DIS

Disney

$129.71

-0.37 (-0.28%)

10:54
10/14/19
10/14
10:54
10/14/19
10:54
Periodicals
Disney splitting $3B media business with Publicis, Omnicom, Campaign reports »

Disney (DIS) is set to…

PUBGY

Publicis

$0.00

(0.00%)

DIS

Disney

$129.71

-0.37 (-0.28%)

OMC

Omnicom

$74.82

0.17 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 24

    Oct

  • 24

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.